CRISCITIELLO, CARMEN
CRISCITIELLO, CARMEN
Dipartimento di Oncologia ed Emato-Oncologia
Advancing equitable and personalized cancer care: Novel applications and priorities of artificial intelligence for fairness and inclusivity in the patient care workflow
2024 M. Cobanaj, C. Corti, E.C. Dee, L. Mccullum, L. Boldrini, I. Schlam, S.M. Tolaney, L.A. Celi, G. Curigliano, C. Criscitiello
PD-L1 testing in metastatic triple-negative breast cancer: Interobserver and interplatform reproducibility of CE-IVD assays for CPS and IC scores
2024 M. Ivanova, C. Frascarelli, B. Cerbelli, M.G. Pignataro, A. Pernazza, K. Venetis, E. Sajjadi, C. Criscitiello, G. Curigliano, E. Guerini-Rocco, P. Graziano, M. Martini, G. D'Amati, N. Fusco
The Evolving Role of Genomic Testing in Early Breast Cancer: Implications for Diagnosis, Prognosis, and Therapy
2024 K. Venetis, C. Pescia, G. Cursano, C. Frascarelli, E. Mane, E. De Camilli, E. Munzone, S. Dellapasqua, C. Criscitiello, G. Curigliano, E. Guerini Rocco, N. Fusco
Cardiotoxicity of Agents Used in Patients With Breast Cancer
2024 P. Zagami, D. Trapani, E. Nicolò, C. Corti, C. Valenza, C. Criscitiello, G. Curigliano, L.A. Carey
Standardized molecular pathology workflow for ctDNA-based ESR1 testing in HR+/HER2- metastatic breast cancer
2024 E. Guerini-Rocco, K. Venetis, G. Cursano, E. Mane, C. Frascarelli, F. Pepe, M. Negrelli, E. Olmeda, D. Vacirca, A. Ranghiero, D. Trapani, C. Criscitiello, G. Curigliano, C. Rolfo, U. Malapelle, N. Fusco
Real-world progression-free survival 2 with CDK4/6 inhibitors plus endocrine therapy and subsequent line: Results from the multicenter SISTER study
2023 S. Morganti, S. Gandini, E. Nicolo, E. Zattarin, C. Corti, A. Verrazzo, P.P.M.B. Giachetti, C. Sposetti, M.G. Razeti, B.T. Salimbeni, L. Boldrini, A.C. Schianca, R. Caputo, C. Vernieri, E. Munzone, M. Lambertini, M. De Laurentiis, G. Viale, G. Curigliano, C. Criscitiello
Trop-2 as an Actionable Biomarker in Breast Cancer
2023 G. Cursano, E. Frigo, E. Sajjadi, M. Ivanova, K. Venetis, E. Guerini-Rocco, C. Criscitiello, G. Curigliano, N. Fusco
Risk of thromboembolic events in patients with metastatic solid tumors treated with PARP inhibitors: A systematic review and meta-analysis of phase 3 randomized controlled trials
2023 G. Castellano, C. Corti, L. Boldrini, L. Gervaso, C. Criscitiello, G. Curigliano
Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents
2023 E. Nicolò, P. Tarantino, O. D'Ecclesiis, G. Antonarelli, L. Boscolo Bielo, A. Marra, S. Gandini, E. Crimini, F. Giugliano, P. Zagami, C. Corti, D. Trapani, S. Morganti, C. Criscitiello, M. Locatelli, C. Belli, A. Esposito, I. Minchella, M. Cristofanilli, S.M. Tolaney, G. Curigliano
Editorial : Diagnosis and Treatment of Breast Cancer in 2022 : The Rise of Novel Molecular Biomarkers
2023 N. Fusco, U. Malapelle, C. Criscitiello
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors
2023 E. Zattarin, D. Presti, L. Mariani, C. Sposetti, R. Leporati, A. Menichetti, C. Corti, C. Benvenuti, G. Fuca, R. Lobefaro, F. Ligorio, L. Provenzano, A. Vingiani, M. Del Vecchio, G. Griguolo, M. Sirico, O. Bernocchi, A. Marra, P. Zagami, E. Agostinetto, F. Jacobs, P. Di Mauro, A. Esposito, C.A. Giorgi, L. Lalli, L. Boldrini, P.P.B. Giacchetti, A.C. Schianca, V. Guarneri, R. Pedersini, A. Losurdo, A. Zambelli, D. Generali, C. Criscitiello, G. Curigliano, G. Pruneri, F. de Braud, M.V. Dieci, C. Vernieri
Artificial intelligence in cancer research and precision medicine: Applications, limitations and priorities to drive transformation in the delivery of equitable and unbiased care
2023 C. Corti, M. Cobanaj, E.C. Dee, C. Criscitiello, S.M. Tolaney, L.A. Celi, G. Curigliano
Metaplastic breast cancer: an all-round multidisciplinary consensus
2023 G. Corso, C. Criscitiello, L. Nicosia, F. Pesapane, E. Vicini, F. Magnoni, A. Sibilio, C. Zanzottera, A.M. De Scalzi, S. Mannucci, M. Marabelli, M. Calvello, I. Feroce, P. Zagami, F.M. Porta, A. Toesca, P. Tarantino, E. Nicolò, G. Mazzarol, C. La Vecchia, B. Bonanni, M.C. Leonardi, P. Veronesi, N. Fusco
Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer?
2023 C. Corti, C. De Angelis, G. Bianchini, L. Malorni, M. Giuliano, E. Hamilton, R. Jeselsohn, K. Jhaveri, G. Curigliano, C. Criscitiello
HER2-Low Breast Cancer: a New Subtype?
2023 C. Corti, F. Giugliano, E. Nicolò, P. Tarantino, C. Criscitiello, G. Curigliano
Unlocking the Resistance to Anti-HER2 Treatments in Breast Cancer: The Issue of HER2 Spatial Distribution
2023 F. Giugliano, A. Carnevale Schianca, C. Corti, M. Ivanova, N. Bianco, S. Dellapasqua, C. Criscitiello, N. Fusco, G. Curigliano, E. Munzone
Tucatinib's journey from clinical development to clinical practice: New horizons for HER2-positive metastatic disease and promising prospects for brain metastatic spread
2023 C. Criscitiello, C. Corti, M. De Laurentiis, G. Bianchini, B. Pistilli, S. Cinieri, L. Castellan, G. Arpino, P. Conte, F. DI MECO, A. Gennari, V. Guarneri, L. Visani, L. Livi, P. Marchetti, F. Puglisi, G. Viale, L. Del Mastro, S. De Placido, G. Curigliano
Evolution of biological features of invasive lobular breast cancer: Comparison between primary tumour and metastases
2023 P. Trillo, J. Sandoval, D. Trapani, E. Nicolò, P. Zagami, F. Giugliano, P. Tarantino, G. Vivanet, L. Ascione, A. Friedlaender, A. Esposito, C. Criscitiello, G. Curigliano
Breast Cancer with Brain Metastasis: Molecular Insights and Clinical Management
2023 M. Ivanova, F.M. Porta, F. Giugliano, C. Frascarelli, E. Sajjadi, K. Venetis, G. Cursano, G. Mazzarol, E. GUERINI ROCCO, G. Curigliano, C. Criscitiello, N. Fusco
Future potential targets of antibody-drug conjugates in breast cancer
2023 C. Corti, L. Boscolo Bielo, A.C. Schianca, B.T. Salimbeni, C. Criscitiello, G. Curigliano